DOCSLIB.ORG

The Toxicologist: Late-Breaking Supplement 2018 LATE-BREAKING ABSTRACT SUBMISSIONS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Toxicologist: Late-Breaking Supplement 2018 LATE-BREAKING ABSTRACT SUBMISSIONS The Toxicologist: Late-Breaking Supplement 2018 LATE-BREAKING ABSTRACT SUBMISSIONS These abstracts also are available via the SOT Mobile Event App and the Online Planner. All Late-Breaking Abstracts are presented on Thursday, March 15, 8:30 am–11:30 am. www.toxicology.org THURSDAY POSTER SESSION MAP March 15, 2018—8:30 AM to 11:30 AM—Hall 1 Poster Set Up—8:00 AM to 8:30 AM Late‐Breaking Poster #s: P101–P484 P580 P579 P578 P577 P576 P575 P574 P573 P572 P571 P570 P569 P568 P567 P566 P565 P564 P563 P562 P561 P560 P559 P558 P557 P533 P534 P535 P536 P537 P538 P539 P540 P541 P542 P543 P544 P545 P546 P547 P548 P549 P550 P551 P552 P553 P554 P555 P556 P532 P531 P530 P529 P528 P527 P526 P525 P524 P523 P522 P521 P520 P519 P518 P517 P516 P515 P514 P513 P512 P511 P510 P509 P485 P486 P487 P488 P489 P490 P491 P492 P493 P494 P495 P496 P497 P498 P499 P500 P501 P502 P503 P504 P505 P506 P507 P508 P484 P483 P482 P481 P480 P479 P478 P477 P476 P475 P474 P473 P472 P471 P470 P469 P468 P467 P466 P465 P464 P463 P462 P461 P437 P438 P439 P440 P441 P442 P443 P444 P445 P446 P447 P448 P449 P450 P451 P452 P453 P454 P455 P456 P457 P458 P459 P460 P436 P435 P434 P433 P432 P431 P430 P429 P428 P427 P426 P425 P424 P423 P422 P421 P420 P419 P418 P417 P416 P415 P414 P413 P389 P390 P391 P392 P393 P394 P395 P396 P397 P398 P399 P400 P401 P402 P403 P404 P405 P406 P407 P408 P409 P410 P411 P412 P388 P387 P386 P385 P384 P383 P382 P381 P380 P379 P378 P377 P376 P375 P374 P373 P372 P371 P370 P369 P368 P367 P366 P365 P341 P342 P343 P344 P345 P346 P347 P348 P349 P350 P351 P352 P353 P354 P355 P356 P357 P358 P359 P360 P361 P362 P363 P364 P340 P339 P338 P337 P336 P335 P334 P333 P332 P331 P330 P329 P328 P327 P326 P325 P324 P323 P322 P321 P320 P319 P318 P317 P293 P294 P295 P296 P297 P298 P299 P300 P301 P302 P303 P304 P305 P306 P307 P308 P309 P310 P311 P312 P313 P314 P315 P316 P292 P291 P290 P289 P288 P287 P286 P285 P284 P283 P282 P281 P280 P279 P278 P277 P276 P275 P274 P273 P272 P271 P270 P269 P245 P246 P247 P248 P249 P250 P251 P252 P253 P254 P255 P256 P257 P258 P259 P260 P261 P262 P263 P264 P265 P266 P267 P268 P244 P243 P242 P241 P240 P239 P238 P237 P236 P235 P234 P233 P232 P231 P230 P229 P228 P227 P226 P225 P224 P223 P222 P221 P197 P198 P199 P200 P201 P202 P203 P204 P205 P206 P207 P208 P209 P210 P211 P212 P213 P214 P215 P216 P217 P218 P219 P220 P196 P195 P194 P193 P192 P191 P190 P189 P188 P187 P186 P185 P184 P183 P182 P181 P180 P179 P178 P177 P176 P175 P174 P173 P149 P150 P151 P152 P153 P154 P155 P156 P157 P158 P159 P160 P161 P162 P163 P164 P165 P166 P167 P168 P169 P170 P171 P172 P148 P147 P146 P145 P144 P143 P142 P141 P140 P139 P138 P137 P136 P135 P134 P133 P132 P131 P130 P129 P128 P127 P126 P125 P101 P102 P103 P104 P105 P106 P107 P108 P109 P110 P111 P112 P113 P114 P115 P116 P117 P118 P119 P120 P121 P122 P123 P124 Entrance Photography in the ToxExpo and all Poster Sessions is prohibited without the consent of exhibitors or poster presenter(s)/ author(s). Please respect your colleagues’ right to privacy. nd UND a E 5 R 1 All text and graphics are © 2018 by the Society of Toxicology. All rights reserved. No text or graphics may be copied or used without written permission from the Society of Toxicology. For further information, please contact SOT Headquarters. For promotional use only. No advertising use is permitted. The Toxicologist: Late-Breaking Supplement 2018 i Thursday, March 15, Poster Session by Location Session Title Abstract #s Poster Board #s Late-Breaking 1: Model Systems 3320–3354a P101–P136 Late-Breaking 2: Toxicokinetics 3355–3366a P137–P149 Late-Breaking 3: Biological Modeling and Computational Toxicology 3367–3390 P150–P173 Late-Breaking 4: Immunotoxicity, Inflammation, Cell Death/Apoptosis 3391–3411 P175–P195 Late-Breaking 5: Ecotoxicology, Pesticides, Chemical and Biological Weapons 3412–3441 P197–P226 Late-Breaking 6: Metals, Ocular, Epidemiology and Public Health 3442–3463 P230–P251 Late-Breaking 7: Neurotoxicity, Genotoxicity/DNA Repair, Receptors 3464–3510a P253–P300 Late-Breaking 8: Exposure and Risk Assessment, Food Safety, Regulation/Policy 3511–3548a P301–P339 Late-Breaking 9: Air Pollution and Respiratory Toxicology, POPs, Carcinogenesis, Cardiovascular 3549–3586 P341–P378 Late-Breaking 10: Nanotoxicology; Stem Cell Biology and Toxicology 3587–3609 P380–P402 Late-Breaking 11: Kidney and Liver; Reproductive and Developmental Toxicology 3610–3638 P404–P432 Late-Breaking 12: Safety Assessment: Pharmaceutical and Non-Pharmaceutical 3639–3667 P437–P465 The Toxicologist: Late-Breaking Supplement 2018 ii Thursday, March 15, Poster Session by Topic Thursday, March 15, Poster Session by Topic TOPIC ABSTRACT #s POSTER BOARD #s Session Title Air Pollution Toxicology 3549–3557 P341–P349 Late-Breaking 9 Alternatives to Mammalian Models 3320–3338 P101–P119 Late-Breaking 1 Animal Models 3342–3354a P123–P136 Late-Breaking 1 Autoimmunity/Hypersensitivity 3340 P121 Late-Breaking 1 Bioinformatics 3383–3384 P166–P167 Late-Breaking 3 Biological Modeling 3375–3381 P158–P164 Late-Breaking 3 Biotransformation/Cytochrome P450 3355–3359 P137–P171 Late-Breaking 2 Carcinogenesis 3575–3580 P367–P372 Late-Breaking 9 Cardiovascular Toxicology/Hemodynamics 3583–3585 P375–P377 Late-Breaking 9 Cell Death/Apoptosis 3406–3411 P190–P195 Late-Breaking 4 Chemical and Biological Weapons 3434–3441 P219–P226 Late-Breaking 5 Computational Toxicology/Data Integration 3367–3374 P150–P157 Late-Breaking 3 Developmental and Juvenile Toxicology 3633–3637 P427–P431 Late-Breaking 11 Disposition/Pharmacokinetics 3360–3363 P142–P145 Late-Breaking 2 Ecotoxicology 3412–3423 P197–P208 Late-Breaking 5 Epidemiology and Public Health 3457–3463 P245–P251 Late-Breaking 6 Exposure Assessment/Biomonitoring 3511–3517 P301–P307 Late-Breaking 8 Food Safety 3537–3548a P327–P339 Late-Breaking 8 Gene Regulation/Signal Transduction/Genotoxicity/DNA Repair 3497–3507 P286–P296 Late-Breaking 7 Immunotoxicity 3391–3400 P175–P184 Late-Breaking 4 Inflammation in Disease 3404–3405 P188–P189 Late-Breaking 4 Kidney 3610–3611 P404–P405 Late-Breaking 11 Liver 3613–3621 P407–P415 Late-Breaking 11 Medical Devices 3656 P454 Late-Breaking 12 Metals 3442–3448 P230–P236 Late-Breaking 6 Nanotoxicology 3587–3601 P380–P394 Late-Breaking 10 Neurotoxicity/Neurodegenerative Disease 3464–3494 P253–P283 Late-Breaking 7 Ocular Toxicology 3453–3456 P241–P244 Late-Breaking 6 Oxidative Injury and Redox Biology 3389 P172 Late-Breaking 3 Persistent Organic Pollutants (POPs) 3568–3574 P360–P366 Late-Breaking 9 Pesticides 3425–3433 P210–P218 Late-Breaking 5 Receptors 3508–3510a P297–P300 Late-Breaking 7 Regulation/Policy 3520–3522 P310–P312 Late-Breaking 8 Reproductive Toxicology 3624–3632 P418–P426 Late-Breaking 11 Respiratory Toxicology 3558–3567 P350–P359 Late-Breaking 9 Risk Assessment 3523–3545 P313–P335 Late-Breaking 8 Safety Assessment: Non-Pharmaceutical 3657–3666 P455–P464 Late-Breaking 12 Safety Assessment: Pharmaceutical-Drug Development and Drug Discovery 3639–3654 P437–P452 Late-Breaking 12 Stem Cell Biology and Toxicology 3602–3609 P395–P402 Late-Breaking 10 The Toxicologist: Late-Breaking Supplement 2018 iii 2018 Society of Toxicology Annual Meeting Late-Breaking Abstracts ABSTRACT NUMBER: 3320 Poster Board Number: P101 TITLE: 3D Histological Characterization of Precision-Cut Lung Slices for Inhalation Studies AUTHORS (FIRST INITIAL, LAST NAME) AND INSTITUTIONS: M. Johnson, T. Villani, and G. Gardner. Visikol Inc., North Brunswick, NJ. Sponsor: E. Lewis KEYWORDS: Particulates; Inhalation Toxicology; Inflammation ABSTRACT: Inhalation studies for allergens and pathogens typically rely upon flow cytometry which provides quantitative analysis of cell proteins associated with immune cells. However, flow cytometry does not provide information on the migration of these cells within the lung and is highly limited in describing the complexities of the lung. Due to these limitations, researchers have begun adopting precision cut lung slices (PCLS) as an in vitro tool as they are able to provide significantly improved in vivo relevancy. However, one of the current limitations in using PCLS models is that they are approx. 250 µm in thickness which is too thick to image through using confocal microscopy. Therefore, it is challenging to capture data from these tissues past a few cell layers due to optical attenuation. Through this work, a rapid tissue clearing technique was applied to PCLS models in a high-throughput/well-plate- compatible format to enable whole mount 3D imaging of the entire PCLS model with confocal microscopy. It was shown that this tissue clearing approach was compatible with several commonly used labels (e.g. DAPI, CD68, tomato lectin, PDGFR, alpha-smooth muscle actin) and that uniform labeling as well as complete tissue characterization could be accomplished. ABSTRACT NUMBER: 3321 Poster Board Number: P102 TITLE: Real Time Monitoring of Human Primary Cell Panel for Evaluating On/Off Target Toxicity of Bi- Specific T Cell Engagers AUTHORS (FIRST INITIAL, LAST NAME) AND INSTITUTIONS: C. Jin, and Y. Abassi. ACEA Biosciences, Inc., San Diego, CA. KEYWORDS: Pharmaceuticals; Alternatives to Animal Testing; Safety Pharmacology ABSTRACT: Cancer immunotherapy empowers the patients’ own immune system to specifically recognize and destroy cancerous cells. Though designed to specifically kill cancer cells, side effects such as cytokine storms and on/off-target toxicity towards normal tissue/organs remain as considerable safety concerns that can be difficult to predict using animal models. Bi-Specific T cell Engagers (BiTEs) are engineered antibodies where the single chain heavy fragments (scFvs)of two monoclonal antibodies are artificially fused together.
Load more

Recommended publications
  • The Effect of Topical Beta-Adrenoceptor Blocking Agents on Pulsatile Ocular Blood Flow
    THE EFFECT OF TOPICAL BETA-ADRENOCEPTOR BLOCKING AGENTS ON PULSATILE OCULAR BLOOD FLOW C. D. MORSMAN, M. E. BOSEM, M. LUSKY and R. N. WEINREB San Diego, California SUMMARY factors (e.g. hypertension, diabetes, peripheral Thirty-three ocular hypertensive patients (21 with vascular disease and vasospasm) to the vascular primary open angle glaucoma and 12 glaucoma system suggest that blood flow in the optic nerve suspects) were randomly assigned to receive either head and retina may be altered in glaucoma.4 Of the timolol, levobunolol or betaxolol in one eye. Pulsatile various vascular beds within the posterior segment, ocular blood flow (POBF) was measured before the choroidal circulation is of particular interest since treatment (baseline) and 2 hours after drop adminis­ it provides the major contribution to the blood flow tration. After 1 week of regular twice-daily dosage, of the optic nerve at the level of the lamina cribrosa.5 POBF was measured again both immediately before Beta-2 adrenergic receptors have been demon­ and 2 hours after drop instillation. All measurements strated in human optic nerve,6 as well as in choroidal were made by an investigator masked to treatment. and retinal blood vessels.7 Blockade of these POBF increased by 11% (p = 0.09) at week 0 after receptors can cause vasoconstrictionS which could levobunolol administration, and by 22% (p = 0.20) at adversely affect visual function if adequate concen­ week 1 before drop administration compared with trations of the drug diffused into the posterior baseline. It dropped by 23% and 25% (p = 0.04 and segment of the eye or were absorbed systemically.
    [Show full text]
  • Use of Emulsions for Intra- and Periocular Injection
    (19) & (11) EP 1 611 879 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/107 (2006.01) 12.08.2009 Bulletin 2009/33 (21) Application number: 04291684.1 (22) Date of filing: 02.07.2004 (54) Use of emulsions for intra- and periocular injection Verwendung von Emulsionen zur intra- und periocularen Injection Utilisation des émulsions pour injection intra- et périoculaire. (84) Designated Contracting States: (74) Representative: de Mareüil-Villette, Caroline et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cabinet Plasseraud HU IE IT LI LU MC NL PL PT RO SE SI SK TR 52 rue de la Victoire 75440 Paris Cedex 09 (FR) (43) Date of publication of application: 04.01.2006 Bulletin 2006/01 (56) References cited: EP-A- 0 521 799 EP-A- 1 020 194 (73) Proprietors: WO-A-02/09667 WO-A-93/18852 • Novagali Pharma S.A. WO-A-94/05298 WO-A-03/053405 91000 Evry (FR) US-A- 5 632 984 • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) • KLANG S H ET AL: "PHYSICOCHEMICAL 75016 Paris (FR) CHARACTERIAZATION AND ACUTE TOXICITY • INSTITUT NATIONAL DE LA SANTE ET DE LA EVALUATION OF A POSITIVELY-CHARGED RECHERCHE MEDICALE (INSERM) SUBMICRON EMULSION VEHICLE" JOURNAL 75013 Paris (FR) OF PHARMACY AND PHARMACOLOGY, • YISSUM RESEARCH DEVELOPMENT COMPANY LONDON, GB, vol. 46, no. 12, December 1994 OF THE HEBREW UNIVERSITY OF JERUSALEM (1994-12), pages 986-993, XP008005426 ISSN: 91390 Jerusalem (IL) 0022-3573 • KLANG S ET AL: "INFLUENCE OF EMULSION (72) Inventors: DROPLET SURFACE CHARGE ON • Rabinovich-Guilatt, Laura INDOMETHACIN OCULAR TISSUE 75015 Paris (FR) DISTRIBUTION" PHARMACEUTICAL • De Kozak, Yvonne DEVELOPMENT AND TECHNOLOGY, NEW 75013 Paris (FR) YORK, NY, US, vol.
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • Canine Red Eye Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO
    PEER REVIEWED Clinical Approach to the CANINE RED EYE Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO he acute red eye is a common clinical challenge for tion of the deep episcleral vessels, and is characterized general practitioners. Redness is the hallmark of by straight and immobile episcleral vessels, which run Tocular inflammation; it is a nonspecific sign related 90° to the limbus. Episcleral injection is an external to a number of underlying diseases and degree of redness sign of intraocular disease, such as anterior uveitis and may not reflect the severity of the ocular problem. glaucoma (Figures 3 and 4). Occasionally, episcleral Proper evaluation of the red eye depends on effective injection may occur in diseases of the sclera, such as and efficient diagnosis of the underlying ocular disease in episcleritis or scleritis.1 order to save the eye’s vision and the eye itself.1,2 • Corneal Neovascularization » Superficial: Long, branching corneal vessels; may be SOURCE OF REDNESS seen with superficial ulcerative (Figure 5) or nonul- The conjunctiva has small, fine, tortuous and movable vessels cerative keratitis (Figure 6) that help distinguish conjunctival inflammation from deeper » Focal deep: Straight, nonbranching corneal vessels; inflammation (see Ocular Redness algorithm, page 16). indicates a deep corneal keratitis • Conjunctival hyperemia presents with redness and » 360° deep: Corneal vessels in a 360° pattern around congestion of the conjunctival blood vessels, making the limbus; should arouse concern that glaucoma or them appear more prominent, and is associated with uveitis (Figure 4) is present1,2 extraocular disease, such as conjunctivitis (Figure 1).
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Glaucoma Medical Treatment: Philosophy, Principles and Practice
    Glaucoma medical CLIVE MIGDAL treatment: philosophy, principles and practice Abstract assessment of these parameters. Indeed There have been numerous recent advances in compounds are under evaluation that affect the the management of glaucoma, not least the function of the optic nerve (via improved blood development of new drugs to help manage supply or improved neuronal cell physiology) raised intraocular pressure. In addition, the but may or may not lower lOP. It may even be concepts of improving blood flow to the optic possible in the future to therapeutically alter the nerve head and neuroprotection are currently human genome, genetically deliver provoking considerable interest. This article neuroprotective substances or aid regeneration considers the aims and philosophy of of the optic nerve axons. glaucoma drug therapy, summarises some of The main aim of glaucoma therapy must still the basic facts and principles of modem be the preservation of visual function. At the glaucoma medications, and suggests a same time, the therapy should not have adverse practical approach to the choice of therapy. side effects and should not affect the quality of life of the patient (by causing either side effects Key words Blood flow, Intraocular pressure, or inconvenience and disruption of daily Neuroprotection, Primary open angle glaucoma, Topical medications lifestyle). The cost of the therapy, both direct and indirect, must also be taken into consideration.s Currently, typical glaucoma management Philosophy consists of lowering the lOP to a satisfactory Primary open-angle glaucoma is a complex and safe target leve1.6 To determine the success disease for which a number of risk factors have of this treatment, the patient must be followed been identified, including intraocular pressure, long-term with routine assessment of lOP, discs age, race and family history.l,2 Due to our and fields to exclude progressive damage.
    [Show full text]
  • Betaxolol Ophthalmic Solution As Alternative Treatment for Patients with Timolol Allergy: a Case Report
    Case Report Betaxolol Ophthalmic Solution as Alternative Treatment for Patients with Timolol Allergy: A Case Report Olivia Müllertz 1,*, Jette Jacobsen 2, Jacob P. Thyssen 3, Anna Horwitz 1,4 and Miriam Kolko 1,4,* 1 Department of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 2 Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 3 Department of Dermatology and Allergy, Herlev-Gentofte Hospital, 2900 Hellerup, Denmark; [email protected] 4 Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, 2600 Glostrup, Denmark * Correspondence: [email protected] (O.M.); [email protected] (M.K.) Received: 24 March 2020; Accepted: 25 June 2020; Published: 30 July 2020 Abstract: Background: To establish if an allergy towards all β-blockers, as a group, should be assumed, if an allergic reaction is observed while using one specific β-blocking agent. Case presentation: The non-selective β-blocker timolol caused a severe allergic ocular reaction in a non-atopic patient with advanced primary open-angle glaucoma. Results: A patch test confirmed timolol allergy. No allergic reaction to other anti-glaucomatous topical drugs was observed, and treatment with the selective β-blocker betaxolol was successfully initiated. Conclusion: Allergy to the non-selective β-blocker timolol does not necessarily predict allergy to the selective β-blocker betaxolol, and betaxolol should therefore not be excluded as an alternative treatment. Keywords: betaxolol; timolol; β-blocker; allergy 1. Introduction Drug allergies are a class of unpredictable adverse reactions that are not related to the pharmacological effect of a drug, and can occur at subtherapeutic doses.
    [Show full text]
  • Betaxolol 0.5% Eye Drops
    Package leaflet: Information for the patient BETAXOLOL 0.5% EYE DROPS Betaxolol (as hydrochloride) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • Your medicine, Betaxolol 0.5% Eye Drops will be referred to as Betaxolol in this leaflet. What is in this leaflet 1. What Betaxolol is and what it is used for 2. What you need to know before you use Betaxolol 3. How to use Betaxolol 4. Possible side effects 5. How to store Betaxolol 6. Contents of the pack and other information 1. What Betaxolol is and what it is used for The active ingredient betaxolol belongs to a group of medicines called beta-blockers. Betaxolol is used to treat raised pressure of eye (intraocular pressure) which occurs in various conditions including glaucoma and ocular hypertension (high pressure in the eye) by reducing the fluid pressure in your eye(s). 2. What you need to know before you use Betaxolol Do not use Betaxolol • if you are allergic (hypersensitive) to betaxolol hydrochloride or beta-blockers or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Betaxolol Hydrochloride
    Contains Nonbinding Recommendations Draft Guidance on Betaxolol Hydrochloride This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Betaxolol hydrochloride Dosage Form; Route: Suspension/drops; ophthalmic Strength: EQ 0.25 % Base Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm in vivo Strength: EQ 0.25 % Base Subjects: Males and females with chronic open-angle glaucoma or ocular hypertension in both eyes Additional comments: Specific recommendations are provided below ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open-angle glaucoma and ocular hypertension comparing the test product versus the reference listed drug (RLD), each applied as one drop in both eyes two times daily at approximately 8:00 a.m., and 8:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open-angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Drug Class Review Ophthalmic Beta-Adrenergic Antagonists
    Drug Class Review Ophthalmic Beta-Adrenergic Antagonists 52:40.08 Beta-Adrenergic Blocking Agents Betaxolol (Betoptic®) Carteolol (Ocupress®) Levobunolol (Betagan®) Metipranolol (Optipranolol®) Timolol (Betimol®, Timoptic®, others) Timolol/Brimonidine (Combigan®) Timolol/Dorzolamide (Cosopt®; Cosopt PF®) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 5 Table 1. Glaucoma Therapies ................................................................................................. 6 Table 2. Summary of Agents .................................................................................................. 7 Disease Overview ...................................................................................................................... 10 Table 3. Summary of Current Clinical Practice Guidelines .................................................. 11 Pharmacology ..............................................................................................................................
    [Show full text]
  • Β Blockers Timolol Betaxolol Carteolol Ocular Hypotensives: List The
    1 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 2 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 3 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) An FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 4 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 5 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three Zioptan (and that’s all we’ll have to say about it) (Latanaprostene bunod) A PGA combo drug 6 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn
    [Show full text]
  • Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry
    Drugs Which May Be Used Based on Licensure Designation Approved Drugs a.) Administration and prescription of pharmaceutical agents for therapeutic purposes. Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes. b.) Administration and prescription of pharmaceutical agents to treat glaucoma. Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma. c.) DEA registration reminder. Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with PDMP standards. d.) Allowable pharmaceutical products. Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug: (1) Topical Anesthetics (i) benoxinate (ii) lidocaine (iii) proparacaine (iv) tetracaine (2) Topical Ocular Lubricants
    [Show full text]